Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Urinary bladder recurrences following ureteroscopic biopsies of upper tract urothelial cancers: a multi-centre observational study with genomic assessment for clonality.
Anbarasan T, Nissar S, Turbitt J, Walls K, McLuckie S, Clark C, Bourdon JC, Tracey J, Bray S, Shamsuddin A, Alcorn J, Jain S, Hislop R, Biyani CS, Nabi G. Anbarasan T, et al. Among authors: turbitt j. Scott Med J. 2023 Feb;68(1):4-13. doi: 10.1177/00369330221134233. Epub 2022 Dec 28. Scott Med J. 2023. PMID: 36576735
Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed.
Meemanage M, Spender LC, Collinson D, Iannetta J, Challapalli P, Turbitt J, Clark C, Baxter M, Murray G, Walsh S, Miedzybrodzka Z, Petty RD. Meemanage M, et al. Among authors: turbitt j. Cancer Chemother Pharmacol. 2021 Mar;87(3):361-377. doi: 10.1007/s00280-020-04187-w. Epub 2020 Nov 9. Cancer Chemother Pharmacol. 2021. PMID: 33169187 Free PMC article.
An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinoma.
Baxter MA, Spender LC, Cairns D, Walsh S, Oparka R, Porter RJ, Bray S, Skinner G, King S, Turbitt J, Collinson D, Miedzybrodzka ZH, Jellema G, Logan G, Kennedy RD, Turkington RC, McLean MH, Swinson D, Grabsch HI, Lord S, Seymour MJ, Hall PS, Petty RD. Baxter MA, et al. Among authors: turbitt j. ESMO Open. 2024 May;9(5):103450. doi: 10.1016/j.esmoop.2024.103450. Epub 2024 May 13. ESMO Open. 2024. PMID: 38744099 Free PMC article. Clinical Trial.
Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trial.
Scanlon E, Lavery A, Albraikat M, Stevenson L, Kennedy C, Byrne R, Walker A, Mullan-Young B, McManus DT, Virdee PS, Elhussein L, Turbitt J, Collinson D, Miedzybrodzka Z, Van Schaeybroeck S, McQuaid S, James JA, Craig SG, Blayney JK, Petty RD, Harkin DP, Kennedy RD, Eatock MM, Middleton MR, Thomas A, Turkington RC. Scanlon E, et al. Among authors: turbitt j. ESMO Open. 2024 Nov;9(11):103930. doi: 10.1016/j.esmoop.2024.103930. Epub 2024 Oct 11. ESMO Open. 2024. PMID: 39395265 Free PMC article.